Janssen collaborates on gene therapies for retinal disorders 05-Feb-2019 By Maggie Lynch Janssen enters collaboration with MeiraGTx for the development and commercialization of retinal disorder gene therapies.
CFDA accepts WuXi-MedImmune’s IND for new mAb 31-Mar-2015 By Zachary Brennan The China Food and Drug Administration (CFDA) has accepted for review an Investigational New Drug (IND) application for WuXi and MedImmune's novel anti-IL6 monoclonal antibody (mAb) for rheumatoid arthritis.
